JP2010540555A - アザシチジン類似体およびその使用 - Google Patents

アザシチジン類似体およびその使用 Download PDF

Info

Publication number
JP2010540555A
JP2010540555A JP2010527139A JP2010527139A JP2010540555A JP 2010540555 A JP2010540555 A JP 2010540555A JP 2010527139 A JP2010527139 A JP 2010527139A JP 2010527139 A JP2010527139 A JP 2010527139A JP 2010540555 A JP2010540555 A JP 2010540555A
Authority
JP
Japan
Prior art keywords
cells
patient
aza
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010527139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540555A5 (enExample
Inventor
ルイス シルバーマン
ジェームス ホランド
Original Assignee
マウント シナイ スクール オブ メディシン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マウント シナイ スクール オブ メディシン filed Critical マウント シナイ スクール オブ メディシン
Publication of JP2010540555A publication Critical patent/JP2010540555A/ja
Publication of JP2010540555A5 publication Critical patent/JP2010540555A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2010527139A 2007-09-26 2008-09-25 アザシチジン類似体およびその使用 Pending JP2010540555A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97543707P 2007-09-26 2007-09-26
PCT/US2008/077669 WO2009042766A1 (en) 2007-09-26 2008-09-25 Azacytidine analogues and uses thereof

Publications (2)

Publication Number Publication Date
JP2010540555A true JP2010540555A (ja) 2010-12-24
JP2010540555A5 JP2010540555A5 (enExample) 2011-08-25

Family

ID=40511851

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010527139A Pending JP2010540555A (ja) 2007-09-26 2008-09-25 アザシチジン類似体およびその使用
JP2010527140A Pending JP2010540556A (ja) 2007-09-26 2008-09-25 アザシチジン類似体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010527140A Pending JP2010540556A (ja) 2007-09-26 2008-09-25 アザシチジン類似体およびその使用

Country Status (15)

Country Link
US (2) US8158605B2 (enExample)
EP (2) EP2205073A4 (enExample)
JP (2) JP2010540555A (enExample)
KR (2) KR20100072230A (enExample)
CN (2) CN101877964A (enExample)
AU (2) AU2008304380A1 (enExample)
BR (2) BRPI0817269A2 (enExample)
CA (2) CA2700267A1 (enExample)
IL (1) IL204690A0 (enExample)
MX (2) MX2010003261A (enExample)
NZ (2) NZ583824A (enExample)
RU (1) RU2488591C2 (enExample)
UA (2) UA99836C2 (enExample)
WO (2) WO2009042767A1 (enExample)
ZA (1) ZA201001660B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540556A (ja) * 2007-09-26 2010-12-24 マウント サイナイ スクール オブ メディシン アザシチジン類似体およびその使用
JP2023153865A (ja) * 2014-12-26 2023-10-18 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2424845A4 (en) * 2009-04-27 2014-03-05 Reddys Lab Ltd Dr PREPARATION OF DECITABIN
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
WO2012142411A1 (en) * 2011-04-15 2012-10-18 Clavis Pharma Asa Systems and methods for detecting hent1 expression in hematological disorders
JP6162709B2 (ja) 2011-11-01 2017-07-12 セルジーン コーポレイション シチジンアナログの経口製剤を使用して癌を治療する方法
CN104271159B (zh) 2012-02-24 2017-11-28 西格诺药品有限公司 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法
US9493500B2 (en) 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
CA2908742C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2015195786A2 (en) 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
WO2017090264A1 (ja) 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
CN109789155B (zh) 2015-12-03 2025-02-07 免疫规划公司 含有地西他滨、5-氮杂胞苷和四氢尿苷的组合物以及其用途
SG11201906404RA (en) 2017-03-20 2019-08-27 Vaccinex Inc Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
US20210363170A1 (en) * 2018-04-19 2021-11-25 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
WO2022035852A1 (en) * 2020-08-10 2022-02-17 The Johns Hopkins University Decitabine analogs for immunological and oncological therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002504068A (ja) * 1995-07-25 2002-02-05 ノルスク・ヒドロ・アーエスアー 改良された治療剤
JP2006507255A (ja) * 2002-09-24 2006-03-02 コローニス ファーマシューティカルズ インコーポレイテッド ウイルス疾患の治療のための１，３，５−トリアジン
JP2007523860A (ja) * 2003-06-20 2007-08-23 コローニス ファーマシューティカルズ インコーポレイテッド ヘテロアリール化合物のプロドラッグ
JP2010540556A (ja) * 2007-09-26 2010-12-24 マウント サイナイ スクール オブ メディシン アザシチジン類似体およびその使用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612384A (fr) 1961-01-10 1962-05-02 Spofa Vereinigte Pharma Werke Procédé de préparation des 1-glycosyle-6-aza-uraciles
GB1050899A (enExample) 1963-12-22
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3998807A (en) * 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
US4172889A (en) * 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
US4405611A (en) 1980-06-27 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Bisulfite stabilization of 5-azacytidine
DE3100478A1 (de) 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4981613A (en) 1986-11-04 1991-01-01 Fuji Photo Film Co., Ltd. Laser light source
CS264454B1 (cs) 1987-08-28 1989-08-14 Piskala Alois 2'-Deoxy-5,6-dihydro-5-azacytidin a způsob jeho výroby
CS264456B1 (cs) 1987-08-28 1989-08-14 Piskala Alois Způsob výroby 5,6-dihydro-S-azacytidinu
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4984396A (en) * 1988-08-29 1991-01-15 Uragami Fukashi Cleaning device
DE3834435A1 (de) * 1988-10-10 1990-06-13 Basf Ag Verbrueckte, wasserloesliche copolymerisate, verfahren zu ihrer herstellung und ihre verwendung
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
EP0526646B1 (en) * 1991-02-19 1997-04-23 Fujitsu Limited Semiconductor device having an isolation region enriched in oxygen and a fabrication process thereof
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
DK0599968T3 (da) 1991-08-14 2000-04-17 Procter & Gamble Pharma Oxazolidinonderivater, der er egnede som antiarytmi- og antifibrilleringsmidler
GB2260319B (en) 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
WO1997005143A1 (en) 1995-07-25 1997-02-13 Asahi Kasei Kogyo Kabushiki Kaisha Novel group 4 transition metal compounds
KR19990036272A (ko) 1995-08-08 1999-05-25 사우코넨 주시 제이 재조합 ｃ-프로테나제와 이의 공정, 제조방법 및 이의 용도
EP0881878A4 (en) 1995-09-15 2004-08-04 Anadys Pharmaceuticals Inc ARYLHYDRAZONE DERIVATIVES AS AN ANTIBACTERIAL AGENT
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EP0914116B1 (en) 1996-05-22 2000-10-11 Protarga Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
JPH10158192A (ja) * 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
KR100483256B1 (ko) * 1997-01-24 2005-04-15 콘파마 아에스 젬시타빈 유도체
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
ES2194320T3 (es) * 1997-06-03 2003-11-16 Itochu Techno Chem Inc Sustancias naturales antivirales o antitumorales y uso de las mismas.
WO1999026958A1 (en) 1997-11-25 1999-06-03 Protarga, Inc. Nucleoside analog compositions and uses thereof
AU2300699A (en) * 1998-02-17 1999-08-30 Ono Pharmaceutical Co. Ltd. Amidino derivatives and drugs containing the same as the active ingredient
WO2000076979A1 (de) 1999-06-09 2000-12-21 Bayer Aktiengesellschaft Pyridincarboxamide und ihre verwendung als pflanzenschutzmittel
JP4979866B2 (ja) 1999-09-08 2012-07-18 リガンド・ファーマシューティカルズ・インコーポレイテッド 肝臓に特異的なドラッグデリバリーのためのプロドラッグ
TR200201023T2 (tr) 1999-10-15 2002-09-23 F. Hoffmann-La Roche Ag Benzodiazepin türevleri.
US6670341B1 (en) * 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
EP1448579A1 (de) 2001-11-21 2004-08-25 Heidelberg Pharma Holding GmbH Phospholipid-derivate von nucleosiden als antitumorale arzneimittel
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
JPWO2004101593A1 (ja) 2003-05-16 2006-07-13 キッセイ薬品工業株式会社 ５’−修飾ヌクレオシド誘導体及びその医薬用途
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20080033172A1 (en) 2003-12-19 2008-02-07 Koronis Pharmaceuticals, Incorporated Mutagenic Heterocycles
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
AU2005210039B2 (en) 2004-02-04 2010-09-02 Neurosearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2007035783A2 (en) * 2005-09-19 2007-03-29 Celator Pharmaceuticals, Inc. Combination formulations of cytidine analogs and platinum agents
RU2405770C2 (ru) 2005-09-27 2010-12-10 Сионоги Энд Ко., Лтд. Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
US20070225248A1 (en) 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002504068A (ja) * 1995-07-25 2002-02-05 ノルスク・ヒドロ・アーエスアー 改良された治療剤
JP2006507255A (ja) * 2002-09-24 2006-03-02 コローニス ファーマシューティカルズ インコーポレイテッド ウイルス疾患の治療のための１，３，５−トリアジン
JP2007523860A (ja) * 2003-06-20 2007-08-23 コローニス ファーマシューティカルズ インコーポレイテッド ヘテロアリール化合物のプロドラッグ
JP2010540556A (ja) * 2007-09-26 2010-12-24 マウント サイナイ スクール オブ メディシン アザシチジン類似体およびその使用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540556A (ja) * 2007-09-26 2010-12-24 マウント サイナイ スクール オブ メディシン アザシチジン類似体およびその使用
JP2023153865A (ja) * 2014-12-26 2023-10-18 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途

Also Published As

Publication number Publication date
IL204690A0 (en) 2010-11-30
US20090209477A1 (en) 2009-08-20
NZ583824A (en) 2012-06-29
BRPI0817234A2 (pt) 2014-09-30
EP2205073A1 (en) 2010-07-14
CA2700267A1 (en) 2009-04-02
ZA201001660B (en) 2011-05-25
AU2008304380A1 (en) 2009-04-02
KR20100072230A (ko) 2010-06-30
US8158605B2 (en) 2012-04-17
MX2010003261A (es) 2010-08-18
UA99836C2 (en) 2012-10-10
CA2700207A1 (en) 2009-04-02
UA99308C2 (ru) 2012-08-10
BRPI0817269A2 (pt) 2014-10-07
CN101877964A (zh) 2010-11-03
AU2008304381A1 (en) 2009-04-02
RU2010116274A (ru) 2011-11-10
EP2197274A4 (en) 2013-03-06
MX2010003002A (es) 2010-07-05
NZ583923A (en) 2012-05-25
RU2010116154A (ru) 2011-11-10
WO2009042767A1 (en) 2009-04-02
CN101815437A (zh) 2010-08-25
JP2010540556A (ja) 2010-12-24
EP2205073A4 (en) 2013-03-06
US20090209482A1 (en) 2009-08-20
WO2009042766A1 (en) 2009-04-02
WO2009042766A9 (en) 2009-05-28
KR20100102092A (ko) 2010-09-20
US8399420B2 (en) 2013-03-19
RU2488591C2 (ru) 2013-07-27
EP2197274A1 (en) 2010-06-23

Similar Documents

Publication Publication Date Title
US8158605B2 (en) Azacytidine analogues and uses thereof
US12239655B2 (en) Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents
KR100374477B1 (ko) 암치료를위한화합물및방법
JP7558963B2 (ja) 修飾されたマイクロｒｎａ及びがんの処置におけるその使用
US20130196938A1 (en) Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent
CN101402667B (zh) 糖基化修饰的一氧化氮供体型齐墩果酸类化合物、其制备方法及用途
WO2019160127A1 (ja) Ｄｎｍｔ阻害剤の用途
US20190054103A1 (en) Method of treatment of tp53 wild-type tumors with 2',2'-difluoro-5-aza-2'-deoxycytidine or prodrugs thereof
CN114423438A (zh) Dnmt抑制剂的用途
JP6431520B2 (ja) フッ化ピリミジン類縁体及びその使用方法
RU2487883C2 (ru) Аналоги азацитидина и их применение
US9493500B2 (en) Fluorinated pyrimidine analogs and methods of use thereof
JP2009518393A (ja) がん治療用ジオキソラン誘導体
WO2018199049A1 (ja) 固形がん治療薬としての新規ｄｎｍｔ阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130828

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140317